[CIS PIDD] [cis-pidd] ADA2 deficiency - Infliximab dosage

Wed May 17 13:57:35 EDT 2017

Dear Sarah, dear all,
I would like to caution:
The fact that etanercept failed in IBD not necessarily predicts its capacity to work in gut inflammation in DADA2.
The gut is a major source for ATP and therefore TNF-mediated gut inflammation in DADA2 is expected.
We all know that IBD is not IBD… (some 17% IBD patients have even responded to abatacept…:-)
Yours, Bodo

****************************************
Univ.-Prof. Dr. med. B. Grimbacher

Scientific-Director
CCI-Center for Chronic Immunodeficiency
UNIVERSITÄTSKLINIKUM FREIBURG
Tel.: 0761 270-77731  Fax: -77744
Breisacherstraße 115, 79106 Freiburg
bodo.grimbacher at uniklinik-freiburg.de<mailto:bodo.grimbacher at uniklinik-freiburg.de>
www.uniklinik-freiburg.de/cci

and

Consultant Immunologist
Institute of Immunity & Transplantation
Dept of Immunology
Royal Free Hospital
UNIVERSITY COLLEGE LONDON
Pond Street
London NW3 2QG
b.grimbacher at ucl.ac.uk<mailto:b.grimbacher at ucl.ac.uk>
www.centreforimmunodeficiency.com

Von: <cis-pidd at lyris.dundee.net<mailto:cis-pidd at lyris.dundee.net>> on behalf of CIS-PIDD <cis-pidd at lists.clinimmsoc.org<mailto:cis-pidd at lists.clinimmsoc.org>>
Antworten an: CIS-PIDD <cis-pidd at lyris.dundee.net<mailto:cis-pidd at lyris.dundee.net>>
Datum: Wednesday 17 May 2017 02:58
An: CIS-PIDD <cis-pidd at lyris.dundee.net<mailto:cis-pidd at lyris.dundee.net>>
Betreff: Re: [cis-pidd] ADA2 deficiency - Infliximab dosage

If there is a significant G.I. inflammatory component, etanercept will not work. It failed in IBD clinical trials.

Sarah C. Glover, DO, AGAF
Director, Inflammatory Bowel and Celiac Disease Program
Associate Professor of Medicine
University of Florida
PO Box 103643 <x-apple-data-detectors://1>
Gainesville, FL 32610<x-apple-data-detectors://1>
http://gastroliver.medicine.ufl.edu/ibd/
Phone (UF Health patient access center): 352-273-9400<tel:352-273-9400>
Phone (IBD research): 352-265-8971<tel:352-265-8971>
Phone (Cell): 312-933-8039<tel:312-933-8039>
Fax 352-265-8979<tel:352-265-8979>

Sent from my iPhone

On May 16, 2017, at 2:15 PM, CIS-PIDD <cis-pidd at lists.clinimmsoc.org<mailto:cis-pidd at lists.clinimmsoc.org>> wrote:

Dear Fabian,

Why would you use infliximab as opposed to etanercept?

Isabelle Meyts, UZ Leuven

Op 16-mei-2017 om 17:00 heeft CIS-PIDD <cis-pidd at lists.clinimmsoc.org<mailto:cis-pidd at lists.clinimmsoc.org>> het volgende geschreven:

Dear all,

I am planning to treat an ADA2 deficient patient with Infliximab and would like to know the dosage and the dosing intervall already used sucessfully.
Is it 5mg/kg at week 0, 2, 6 and thereafter every 8 weeks?

Thank you and best regards,

Fabian

Fabian Hauck, MD, PhD

Head Immunodeficiency Unit and Immunological Diagnostics Laboratoy
Pediatrics / Pediatric Hematology and Oncology / Immunology (DGfI)

Dr. von Hauner Children’s Hospital
Klinikum der Universität München
Lindwurmstr. 4, 80337 München
Germany

Tel.: +49 89 4400-53931
Fax: +49 89 4400-53964
E-Mail: fabian.hauck at med.uni-muenchen.de<mailto:fabian.hauck at med.uni-muenchen.de>

www.klinikum.uni-muenchen.de<http://www.klinikum.uni-muenchen.de/>

<image001.png>

Das Klinikum der Universität München ist eine Anstalt des öffentlichen Rechts (AöR)
The Klinikum der Universität München is an Institution under Public Law

---

You are currently subscribed to cis-pidd as: Isabelle.Meyts at uzleuven.be<mailto:Isabelle.Meyts at uzleuven.be>.

To unsubscribe click here: http://cts.dundee.net/u?id=96396636.15f0ef7c3f65602e498cc8265c1ae62d&n=T&l=cis-pidd&o=4376767

(It may be necessary to cut and paste the above URL if the line is broken)

or send a blank email to leave-4376767-96396636.15f0ef7c3f65602e498cc8265c1ae62d at lyris.dundee.net<mailto:leave-4376767-96396636.15f0ef7c3f65602e498cc8265c1ae62d at lyris.dundee.net>

---

You are currently subscribed to cis-pidd as: sarah.glover at medicine.ufl.edu<mailto:sarah.glover at medicine.ufl.edu>.

To unsubscribe click here: http://cts.dundee.net/u?id=109023005.a6f267185a4a4f2c4ee42aedf0868c4d&n=T&l=cis-pidd&o=4377143

(It may be necessary to cut and paste the above URL if the line is broken)

or send a blank email to leave-4377143-109023005.a6f267185a4a4f2c4ee42aedf0868c4d at lyris.dundee.net<mailto:leave-4377143-109023005.a6f267185a4a4f2c4ee42aedf0868c4d at lyris.dundee.net>

---

You are currently subscribed to cis-pidd as: bodo.grimbacher at uniklinik-freiburg.de<mailto:bodo.grimbacher at uniklinik-freiburg.de>.

To unsubscribe click here: http://cts.dundee.net/u?id=96396431.4f2a33ac30bfa58d3a76b5fb5b03d33a&n=T&l=cis-pidd&o=4377989

(It may be necessary to cut and paste the above URL if the line is broken)

or send a blank email to leave-4377989-96396431.4f2a33ac30bfa58d3a76b5fb5b03d33a at lyris.dundee.net<mailto:leave-4377989-96396431.4f2a33ac30bfa58d3a76b5fb5b03d33a at lyris.dundee.net>

---
You are currently subscribed to cis-pidd as: pagid at list.clinimmsoc.org.
To unsubscribe click here: http://cts.dundee.net/u?id=96396833.5a9591ccd1e327fe6bc4d1543298c482&n=T&l=cis-pidd&o=4379373
or send a blank email to leave-4379373-96396833.5a9591ccd1e327fe6bc4d1543298c482 at lyris.dundee.net
-------------- next part --------------
An HTML attachment was scrubbed...
URL: <https://pairlist7.pair.net/pipermail/pagid/attachments/20170517/946a7ca0/attachment-0001.html>